圣达生物(603079) - 2025 Q2 - 季度业绩预告

Current Period Performance Forecast The company anticipates substantial growth in its 2025 semi-annual performance, with significant increases in both net profit and non-recurring net profit attributable to shareholders 2025 Semi-Annual Performance Forecast vs. Prior Period | Indicator | 2025 Semi-Annual Forecast | 2024 Semi-Annual (Prior Period) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | RMB 35 million - RMB 45 million | RMB 16.4948 million | 112.19% - 172.81% | | Net Profit Attributable to Shareholders After Non-Recurring Items | RMB 32 million - RMB 42 million | RMB 5.1514 million | 521.19% - 715.31% | - This performance forecast applies to situations where profitability is achieved, and net profit increases by over 50% compared to the same period last year[3] - The performance forecast period is from January 1, 2025, to June 30, 2025[4] - The company explicitly states that this performance forecast data has not been audited by a certified public accountant[5] Prior Period Performance Overview Key financial data for the first half of 2024 is provided as a benchmark, including net profit and non-recurring net profit attributable to the parent company 2024 Semi-Annual Key Financial Data | Indicator | 2024 Semi-Annual Data | | :--- | :--- | | Total Profit | RMB 24.1930 million | | Net Profit Attributable to Shareholders | RMB 16.4948 million | | Net Profit Attributable to Shareholders After Non-Recurring Items | RMB 5.1514 million | | Earnings Per Share | RMB 0.1/share | Main Reasons for Performance Pre-Increase Performance growth is primarily driven by optimized internal management, enhanced operational efficiency, and successful market expansion strategies - Internal Management Improvement: Continuous advancement of refined management and technological upgrades has enhanced operational efficiency and optimized costs[7] - Successful Market Strategy: Deepening differentiated competitive strategies and increasing market expansion efforts for bio-preservatives and functional ingredients have driven growth in this business segment[7] Risk Warning and Other Disclosures The company confirms no significant uncertainties affecting the forecast, reminding investors that preliminary data is subject to the final audited semi-annual report - The company confirms there are no other uncertain factors that could significantly impact the content of this performance forecast[8] - The company reminds investors that the forecast data is a preliminary calculation by the finance department and has not been audited; the final accurate data will be based on the company's officially disclosed 2025 semi-annual report, and investment risks should be noted[9]